AlzeCure presents at Redeye Neurology Theme Event on October 11

Nyheter AlzeCure Pharma Nyheter alla bolag

Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här

Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

AlzeCure presents at Redeye Neurology Theme Event on October 11

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company is participating at Redeye Neurology Theme Event on October 11, 2023 at 10:45 CEST, where CEO Martin Jönsson will present and answer questions about the latest developments and the company's plans going forward.

Watch the livestream via https://www.redeye.se/events/910705/redeye-neurology-seminar-cns where the presentation also will be available afterwards.

The presentation will also be available afterwards on AlzeCure's company page at Redeye www.redeye.se/company/alzecure-pharma, and on AlzeCure's website www.alzecurepharma.se/en/presentations-and-interviews/.

About AlzeCure Pharma AB (publ)

AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer’s disease and pain – indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.

NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer’s disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson’s disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer’s disease and comprises two drug candidates. Painless is the company’s research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.

FNCA Sweden AB, +46(0)8 528 00 399 info@fnca.se, is the company’s Certified Adviser. For more information, please visit www.alzecurepharma.se.

Datum	2023-10-03, kl 10:00
Källa	MFN

Bifogade filer

AlzeCure presents at Redeye Neurology Theme Event on October 11

LOGGA IN

AlzeCure Pharma

Affiliate

AlzeCure presents at Redeye Neurology Theme Event on October 11